Tolerogenic properties of dendritic cells (DC), particularly those in the immature state, and
their therapeutic potential are increasingly being recognized. Among seral distinct
approaches to generate stably immature DC, pharmacologic manipulation stands out as a
promising and clinically applicable option. We have shown recently that the immunophilin
ligand rapamycin (Rapa) can inhibit DC maturation and their effector functions. Here, we
examined the impact of Rapa exposure on subsequent alloantigen (Ag) presentation by …